New drug may stop kidney transplants from failing
NCT ID NCT06751602
First seen Nov 04, 2025 · Last updated May 05, 2026 · Updated 31 times
Summary
This study tests whether adding the drug belumosudil to standard anti-rejection medicines can prevent scarring in new kidney transplants. Scarring often leads to transplant failure over time. About 40 adults receiving a first or second kidney will take either the drug or a placebo for one year. The goal is to see if the drug reduces serious side effects and slows kidney damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REJECTION CHRONIC RENAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Research Institute
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.